Multiple Sclerosis Therapies Market Size Worth $$28.00 billion by 2026 at 2.5% CAGR with Global Analysis of 10+ companies

Multiple Sclerosis Therapies Market by Type (Immunosuppressants and Immunomodulators) and Route of Administration (Oral, Injectable, and Intravenous): Global Opportunity Analysis and Industry Forecast, 2019-2026.

The global multiple sclerosis (MS) therapies market was valued at $22.99 billion in 2018, and is projected to reach $28.00 billion by 2026, registering a CAGR of 2.5% from 2019 to 2026.

Request Sample Copy of multiple sclerosis (MS) therapies market Research Report @

https://www.alliedmarketresearch.com/request-sample/1438

Significant rise in number of pipeline drugs is a key factor that contributes toward the growth of the global multiple sclerosis therapies market along with increase in patient base suffering from multiple sclerosis. Furthermore, surge in number of patient assistance programs and similar initiatives undertaken by the government of various countries are anticipated to further boost the demand for multiple sclerosis therapies in coming future.

What are the key trends in the MS Therapies market report?

The key trends in the MS Therapies market are introduction of novel drugs to treat multiple sclerosis and alarming increase in patient base suffering from MS.

Covid-19 Scenario-

According to the National MS society's National Medical Advisory Committee, the decisions regarding disease modifying therapies should be collaboratively taken between the person with MS and his healthcare provider during the COVID-19 pandemic.

On the basis of their expert advice the society recommends that people with MS should follow CDC guidelines along with additional information for people at risk for serious illness from COVID 19. People with MS should continue DMTs and discuss precise risks with their MS healthcare provider before stopping a DMT.

On the other hand, the pharmaceutical providers all over the world are tackling the situation in terms of production to meet essential requirements. Moreover, the medicinal and other requirement for therapies may witnessed either shortage or delay due to disruption in the supply chain.

Request Customization [ "COVID-19 impact" ]

https://www.alliedmarketresearch.com/request-for-customization/1438?reqfor=covid

Key Players in Global Multiple Sclerosis Drugs Market

Bayer AG
Biogen
Bristol-Myers Squibb Company
ABBVIE INC.
F. Hoffmann-La Roche Ltd.
Merck KGaA
Novartis AG
Pfizer Inc.
SANOFI
Teva Pharmaceutical Industries Ltd.

Directly Purchase a copy of the report with TOC @

https://www.alliedmarketresearch.com/purchase-enquiry/1438

The oral segment to maintain its leadership position during the forecast period-

Based on route of administration, the oral segment contributed to the highest market share with more than two-fifths of the global multiple sclerosis therapies market share in 2018, and is estimated to maintain its leadership position during the forecast period. Furthermore, the segment is estimated to generate the fastest CAGR of 2.8% from 2019 to 2026. This is due to significant therapeutic advances in the new orally administered drugs approved for the MS treatment.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.